Price$2.03-0.05 (-2.17%)
2025-09-042025-12-05
News · 26 weeks290%
2025-11-022026-04-26
Mix090d
No activity.
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Mural Oncology plcSCHEDULE 13G/A - Mural Oncology plc (0001971543) (Subject)
- SECSEC Form 15-12G filed by Mural Oncology plc15-12G - Mural Oncology plc (0001971543) (Filer)
- SECSEC Form EFFECT filed by Mural Oncology plcEFFECT - Mural Oncology plc (0001971543) (Filer)
- SECSEC Form S-8 POS filed by Mural Oncology plcS-8 POS - Mural Oncology plc (0001971543) (Filer)
- SECSEC Form S-8 POS filed by Mural Oncology plcS-8 POS - Mural Oncology plc (0001971543) (Filer)
- SECSEC Form S-8 POS filed by Mural Oncology plcS-8 POS - Mural Oncology plc (0001971543) (Filer)
- SECSEC Form POS AM filed by Mural Oncology plcPOS AM - Mural Oncology plc (0001971543) (Filer)
- INSIDERSEC Form 4 filed by Director Hickey Benjamin4 - Mural Oncology plc (0001971543) (Issuer)
- INSIDERChief Executive Officer Loew Caroline returned 293,059 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Mural Oncology plc (0001971543) (Issuer)
- INSIDERSEC Form 4 filed by Director Cuss Francis M4 - Mural Oncology plc (0001971543) (Issuer)
- INSIDERSEC Form 4 filed by Director Jackson Scott Thomas4 - Mural Oncology plc (0001971543) (Issuer)
- PRXOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plcEMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously announced acquisition of the entire issued and to be issued share capital of Mural Oncology plc ("Mural") (NASDAQ:MURA) (the "Acquisition") pursuant to an Irish High Court sanctioned scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme"). Mural shareholders received $2.035 in cash per share (the "Consideration"). The Acquisition was approved by Mural shareholders at a special meeting of shareholders convened pursuant to section 450(1) of the Ir
- INSIDERSEC Form 4 filed by Director Golumbeski George4 - Mural Oncology plc (0001971543) (Issuer)
- INSIDERSEC Form 4 filed by Director Minegishi Sachiyo4 - Mural Oncology plc (0001971543) (Issuer)
- INSIDERChief Legal Officer Keson-Brookes Maiken returned 68,834 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Mural Oncology plc (0001971543) (Issuer)
- INSIDERChief Medical Officer Goodman Vicki L returned 84,727 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Mural Oncology plc (0001971543) (Issuer)
- INSIDERChief Financial Officer Cutler Adam D. returned 99,290 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Mural Oncology plc (0001971543) (Issuer)
- SECSEC Form 25-NSE filed by Mural Oncology plc25-NSE - Mural Oncology plc (0001971543) (Subject)
- SECMural Oncology plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update8-K - Mural Oncology plc (0001971543) (Filer)
- PRMural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of AcquisitionWALTHAM, Mass. and DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (NASDAQ:MURA) ("Mural") announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the "Scheme") pursuant to which XRA 5 Corp. ("Sub"), a wholly-owned subsidiary of XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty") will acquire the entire issued and to be issued share capital of Mural, became effective today, 5 December 2025 (the "Effective Date"). Distribution of cheques and crediting of DTC participant accounts for the cash consideration paid by Sub to Scheme Shareholders under the terms of the Scheme is expected to commence as soon
- PRMural Oncology Announces Sanction of the Scheme by the High CourtWALTHAM, Mass. and DUBLIN, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (NASDAQ:MURA) ("Mural") announces that the High Court of Ireland has today sanctioned the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the "Scheme") pursuant to which XRA 5 Corp. ("Sub"), a wholly-owned subsidiary of XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty"), will acquire the entire issued and to be issued share capital of Mural (the "Acquisition"). The Scheme and the Acquisition will become effective on delivery of the Court Order to the Irish Registrar of Companies. Delivery of the Court Order to the Irish Registrar of Companies
- PRMural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA RoyaltyWALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA) ("Mural") announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty"), XRA 5 Corp. ("Sub") and Mural announced on August 20, 2025 (the "Transaction Agreement"), the Additional Price Per Share (as defined in the Transaction Agreement) has been finally determined in accordance with Clause 2.4 of the Transaction Agreement as $0.000. As a result, the total cash consideration payable to Mural shareholders on closing of the Acquisition (as defined below) will be $2.035 in cash per share. As previously announced on Au
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Mural Oncology plcSCHEDULE 13G/A - Mural Oncology plc (0001971543) (Subject)
- INSIDERChief Medical Officer Goodman Vicki L sold $10,475 worth of Ordinary Shares (5,036 units at $2.08), decreasing direct ownership by 6% to 84,727 units (SEC Form 4)4 - Mural Oncology plc (0001971543) (Issuer)
- SECSEC Form 144 filed by Mural Oncology plc144 - Mural Oncology plc (0001971543) (Subject)
MURA FAQ
5 questionsWhere does MURA stock trade?
Mural Oncology plc (MURA) is listed on NASDAQ.What sector and industry is MURA in?
Mural Oncology plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about MURA?
Mural Oncology plc has had 4 recent analyst actions on file. The most recent action was from Morgan Stanley: Equal-Weight on 2025-03-25. Recent price targets range from $1300.00 to $1800.00.What companies are similar to MURA?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare MURA side-by-side with any of them on Quantisnow.How can I track MURA on Quantisnow?
Quantisnow aggregates Mural Oncology plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MURA to receive live email and push alerts on every new disclosure.